| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2011: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2010: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2009: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Research Abstract |
We performed a developmental research on recombinant oncolytic viruses that possess certain antitumor functions and are useful for brain tumor therapy. A third-generation oncolytic herpes simplex virus type 1(G47.) was used as the backbone to insert foreign sequences. Oncolytic viruses that express immune-stimulatory factors or luciferase, or that use tumor-specific promoters, were constructed and evaluated, and proved to be highly useful. G47. is expected as a new drug for brain tumors in the near future, and a progress has been made in the basic development of next generation onoclytic virus therapy.
|
